Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway

Shu Wakino, Koichi Hayashi

研究成果: Review article

3 引用 (Scopus)

抜粋

Although PPARgamma ligands have an antihypertensive effect in vivo, the precise mechanism has not been fully elucidated. We examined their effects on Rho/Rho kinase pathway, a key regulator of vascular tone. In cultured rat aortic smooth muscle cells, Rho kinase activated by angiotensin II was suppressed by the pretreatment with pioglitazone and troglitazone. The roles of Vav, a GTP/GDP exchange factor upregulating Rho kinase activity, and SHP-2, protein tyrosine phosphatase that dephosphorylated Vav and subsequently inactivated Rho kinase were examined. Both pioglitazone and troglitazone upregulated SHP-2, particularly in the cytosolic fraction, and the SHP-2-bound Vav, and reduced the phosphorylation of Vav. These mechanisms may contribute to the hemodynamic, in addition to metabolic, action by PPARgamma ligands in hypertensive, metabolic syndrome.

元の言語English
ページ(範囲)693-699
ページ数7
ジャーナルNippon rinsho. Japanese journal of clinical medicine
63
発行部数4
出版物ステータスPublished - 2005 4

ASJC Scopus subject areas

  • Medicine(all)

フィンガープリント Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用